Articles related to SARCOMA

A phase 3 trial comparing doxorubicin-trabectedin combination therapy to doxorubicin alone in advanced leiomyosarcoma patients demonstrated a median overall survival of 33 months versus 24 months, respectively.

A medical student’s journey through misdiagnosis and treatment of a rare soft tissue sarcoma reveals critical gaps in patient care and decision-making processes.

Dedifferentiated liposarcoma, a malignancy with significant metastatic potential, requires precise diagnosis through MRI, PET scans, and genetic testing. MDM2 and CDK4 are pivotal markers for distinguishing DDL from other sarcomas.

The recent uncovering of KSHV’s method of commandeering cell metabolism for cancer progression not only highlights a novel therapeutic target but also emphasizes the need for vigilant monitoring in immunocompromised patients, where such viral activations are more likely to precipitate aggressive cancers.

The recent phase 2 study on atezolizumab shows promising results in inducing sustained responses in advanced ASPS patients.

Meaningful advances in sarcoma treatment have been painfully slow. Modern immunotherapy may change that. The article referenced by this editorial reports the results of CMB305 plus atezolizumab or atezolizumab alone in patients with NY-ESO-1–expressing synovial or myxoid round cell liposarcoma. The relevance of this study furthers the data using novel immunotherapeutic strategies, which generate B- and T-cell responses for two rare sarcomas that can serve as a foundation for future trials.